Apollomics Faces Nasdaq Delisting Risk, Terminates $3.8M Licensing Deal
Summary
Apollomics Inc. received a Nasdaq delisting notice for low market value and terminated a licensing agreement due to a partner's failure to pay $3.8 million, regaining rights to its lead asset.
Key Events
-
Nasdaq Delisting Notice Received
Apollomics Inc. received a notice from Nasdaq for non-compliance with the minimum Market Value of Listed Securities (MVLS) requirement of $35 million. The company has 180 calendar days, until December 15, 2026, to regain compliance by maintaining an MVLS above $35 million for at least 10 consecutive business days.
-
Material Licensing Agreement Terminated
The company terminated its Collaboration and License Agreement with Launxp International Co., Ltd. due to Launxp's failure to remit a $3.8 million upfront payment balance. Apollomics has initiated a dispute resolution process to recover the unpaid amount and has regained global rights (outside Mainland China and Macau) to its lead clinical asset, vebreltinib (APL-101).
Analysis
Apollomics Inc. received a Nasdaq notice for failing to meet the minimum Market Value of Listed Securities, initiating a 180-day compliance period to avoid potential delisting. This is a significant risk to the company's public trading status. Concurrently, the company terminated a collaboration agreement with Launxp International Co., Ltd. due to an unpaid $3.8 million balance. While Apollomics regains global rights to its lead asset, vebreltinib, the immediate loss of this substantial payment, especially following a recent 'going concern' disclosure, further strains the company's financial position.
At the time of this filing, APLM was trading at $20.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45M. The 52-week trading range was $3.66 to $42.12. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.